ETF Channel Analyst Sees RSSL Reaching $109, Analysts Expect 19.46% Upside

The Global X Russell 2000 ETF (RSSL) has a weighted average implied analyst target price of $108.98 per unit, indicating a 19.46% upside from its recent trading price of $91.22. Key holdings with notable upside to their analyst target prices include Alpha Teknova Inc (TKNO), DiaMedica Therapeutics Inc (DMAC), and Nano-X Imaging Ltd (NNOX).

The Global X Russell 2000 ETF (RSSL) has garnered attention from analysts who see significant upside potential in the fund's holdings. With a weighted average implied analyst target price of $108.98 per unit, this represents a 19.46% upside from the ETF's recent trading price of $91.22 [1]. This optimism is driven by several key holdings within the ETF, each with notable upside to their analyst target prices.

One such holding is Alpha Teknova Inc (TKNO), which has an implied analyst target price of $25.00 per share, indicating a 40.70% upside from its recent trading price of $17.75. This substantial upside suggests that analysts are optimistic about the company's future performance and growth prospects.

Another notable holding is DiaMedica Therapeutics Inc (DMAC), with an implied analyst target price of $12.00 per share, representing a 36.15% upside from its recent trading price of $8.80. Analysts' optimism for this biotechnology company is likely driven by its innovative drug pipeline and potential for significant growth in the healthcare sector.

Additionally, Nano-X Imaging Ltd (NNOX) has an implied analyst target price of $1.50 per share, indicating a 35.00% upside from its recent trading price of $1.10. Analysts' confidence in this healthcare technology company is likely due to its advanced imaging technology and potential applications in various medical fields.

While these target prices suggest strong analyst sentiment, it is essential for investors to conduct their own research and consider the broader market conditions and company-specific developments. Analyst targets can be influenced by various factors, and it is crucial to assess whether these targets are justified or if they reflect overly optimistic expectations.

References:
[1] https://www.nasdaq.com/articles/analysts-see-21-gains-ahead-vtwg